Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Phase IIIb, randomized, multicenter, double-blind, prospective study to evaluate the efficacy
and safety of a daily fixed-dose combination of glimepiride / vildagliptin / metformin in
patients with type 2 diabetes with a history of dual treatment failure and combined or
individual oral antidiabetics with SGLT2 / Metformin, Biguanide / Sulfonylurea, Sulfonylurea
/ iDPP4 or Biguanide / iDPP4. To evaluate the changes in the percentage of HbA1c at 3 and 6
months with regard to their baseline measurement.